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Abstract: This study investigated the immunohistochemical staining characteristics of glutathione-S-transferase (GST)
alpha, pi, mu, and theta in prostatic acinar adenocarcinoma (PCA), prostatic intraepithelial neoplasia (PIN), and benign
prostatic tissues from 19 patients. Relationships between GST isoenzyme expression in benign, PIN, and PCA tissue were
examined by the Wilcoxon signed-rank test and clinicopathological data were examined by the Spearman correlation
rank test. When the benign, PIN, and PCA tissues from these cases were compared according to their staining intensity,
GST alpha, pi, mu, and theta expressions in tumor cells were significantly lower than in benign epithelial cells (P < 0.05).
The GST alpha class displayed the lowest level of expression in PIN and PCA. Expression of GST pi was lower in PCA
tissue than in PIN and benign epithelial tissue (P < 0.05). We hypothesize that carcinogenesis in the prostate results from
impaired cellular handling of mutagenic agents owing to reduction or loss of expression of multiple GST isoenzymes
and other detoxifying and antimutagenesis agents. This study confirms the down-regulation of GST isoenzymes in
PCA of the prostate and shows that the loss of GST isoenzyme expression is a phenotype associated with malignant
transformation. There was no statistical relationship between GST isoenzyme expression and the clinicopathological
data (age, Gleason score, and total serum prostate-specific antigen levels) (P > 0.05).
Key words: Prostate acinar adenocarcinoma, prostatic intraepithelial neoplasia, glutathione-S-transferase,
immunohistochemistry

Introduction
Glutathione-S-transferases (GSTs) are a family of
enzymes that detoxify intracellular xenobiotics,
primarily by catalysis of the nucleophilic attack of
reduced glutathione on electrophilic compounds
(1,2). Since conjugation to glutathione renders these
potential carcinogens chemically inactive and hence

incapable of forming DNA adducts, it has been
hypothesized that GSTs protect against neoplastic
transformation (3). In humans, the cytosolic GSTs
can be divided into 7 major classes: alpha (A), mu
(M), pi (P), sigma (S), theta (T), omega (O), and
zeta (Z). These isoenzymes are found in a wide
range of normal tissues, and their expression has
significant biological and clinical implications,
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including drug resistance and carcinogenesis (4,5).
Although GSTP can be detected in normal prostatic
epithelium, prostate cancer cells fail to express GSTP
polypeptides. Loss of GSTP function also appears to
be characteristic of prostatic intraepithelial neoplasia
(PIN) lesions (6). The loss of GSTP expression was
associated with hypermethylation of regulatory
sequences near the gene locus. As GSTs are inducible
enzymes, enzymatic activities were thought to be
linked to genetic variations and involvement of
several cytochrome P450 (CYP) and/or GST genetic
polymorphisms, especially for tobacco-related
cancers (7). The neoplasms express higher levels of
GST than normal tissues. In this study, we assessed
the cellular prevalence and distribution of GSTP,
GSTM4, GSTA, and GSTT1 isoenzymes in matched
human tissue samples of benign prostate, PIN, and
acinar adenocarcinoma of the prostate (PCA).
Materials and methods
Patients
For
immunohistochemical
studies,
radical
prostatectomy tissues from 19 Keçiören Education
and Research Hospital patients with PCA were
used. For all patients, total serum prostate-specific
antigen (PSA) levels, patient age, and Gleason
score were included. Operation material was
examined macroscopically by 2 pathologists in each
case. Radical prostatectomy materials were fixed
overnight, and serial tissue samples were taken at
2-mm intervals from apex to base. If the tumor
could be grossly identified as a gray, firm area, 2
sections were taken: 1 from the tumor tissue, and 1
from the macroscopically normal tissue and tissue
peripheral to the tumor tissue. If it was difficult to
see macroscopically, PCA, PIN, and benign prostatic
areas were detected microscopically and paraffin
blocks were chosen.
Immunohistochemical staining
The tissues were fixed in 10% buffered formalin and
embedded in paraffin blocks. Sections 4 µm thick were
cut, and 1 section was stained with hematoxylin and
eosin to observe the tissue morphology and tumor
score. For immunohistochemistry, endogenous
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peroxidase activity was blocked by incubating the
sections in 1% hydrogen peroxide (v/v) in methanol
for 10 min at room temperature (RT). The sections
were subsequently washed in distilled water for 5
min, and antigen retrieval was performed for 3 min
using 0.01 M citrate buffer (pH 6.0) in a domestic
pressure cooker. The sections were transferred in
0.05 M Tris-HCl (pH 7.6) containing 0.15 M sodium
chloride (TBS). After washing in water, the sections
were incubated at RT for 30 min with either normal
swine serum (for anti-GSTA, anti-GSTP, and antiGSTM4 at 1:20) or normal goat serum (for antiGSTT1 at 1:20) diluted in TBS to block nonspecific
binding. The sections were then covered with the
primary antibodies and diluted at 1:100 for antiGSTA and GSTP, 1:50 for anti-GSTM4, and 1:500 for
anti-GSTT1 in TBS at 4 °C overnight (monoclonal
antibody against hGSTT1 raised in mouse, Labas
International Limited, Estonia; polyclonal antibodies
against GSTA, GSTM4, and GSTP raised in rabbit,
Lab Vision, Thermo Shandon, USA). After washing
in TBS (15 min), sections were incubated at RT for
1 h with secondary antibody (swine-antirabbit Igbiotinylated for anti-GSTA, GSTP, and GSTM4, or
goat-antimouse Ig-biotinylated for anti-GSTT1) at
a dilution of 1:100. This was followed by treatment
with avidin–biotin peroxidase complex (Dakopatts,
Denmark). Diaminobenzidine was used to visualize
peroxidase activity in the tissues. Nuclei were
lightly counterstained with hematoxylin, and then
the sections were dehydrated and mounted. Both
positive and negative controls were included in each
run. Positive controls consisted of sections of normal
human liver for GSTA, GSTM4, and GSTT1 and
normal human small intestine for GSTP. TBS was
used in place of the primary antibody for negative
controls. Immunohistochemically stained sections
were examined by light microscopy, and distribution,
localization, and the intensity of immunostaining
were recorded. Brown color in the cytoplasm and/
or nucleus of epithelial cells was evaluated as positive
staining. Scoring was performed by 2 observers
without knowledge of patient data. Scoring differences
between observers were resolved by consensus. For
each antibody, the intensity of staining was graded
semiquantitatively as follows: score 0, negative
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staining; score 1, weak staining; and score 2, strong
staining.

There were no statistically significant differences
in GSTT1 and GSTM4 expression between benign
and tumor epithelium (Table). Of benign epithelium,
53% was GSTM4-positive; however, 58% of PIN
and 37% of tumors were considered to have GSTM4
expression (Figure 2). Similarly, both benign
epithelium and PIN showed 79% GSTT1-positive
expression; however, there was no statistically
significant difference (Table; Figure 3).

Statistical analysis
For each isoenzyme, staining scores in benign tissue,
intraepithelial neoplasia, and cancer epithelium
were compared statistically. The relationship among
expression of GST isoenzymes in benign tissue,
intraepithelial neoplasia, and cancer epithelium was
analyzed using the Wilcoxon signed-rank test. The
correlation between expressions of GST isoenzymes
and clinicopathological data was also examined using
Spearman’s correlation rank tests. Data analysis was
performed using SPSS 11.5 for Windows (SPSS Inc.,
Chicago, IL, USA). A P-value of less than 0.05 was
considered statistically significant; however, for all
possible multiple comparison tests, the Bonferroni
adjustment was applied to control type I error.

There was a statistically significant difference in
the GSTP expression between cancer and benign
epithelium and PIN (P < 0.05). GSTP expression
was seen at 32% in tumor epithelium (Figure 4), but
89% of the benign samples were considered to have
GSTP expression. Thus, stronger GSTP expression
was observed in benign epithelium than in tumor
epithelium in human prostate cancers.
According to the Bonferroni correction method,
there was no statistically significant difference in
the staining levels of other GST isoenzymes among
benign, PIN, and PCA tissues (P > 0.05).

Results
The median patient age was 66 years (minimum: 54,
maximum: 77), the median value of patient Gleason
scores was 6 (minimum: 5, maximum: 9), and the
median value of total PSA was 9.9 (minimum: 0.68,
maximum: 28.03).

The clinical and pathologic characteristics of
the prostate cancers and the levels of GSTA, GSTP,
GSTM4, and GSTT1 expression were correlated
separately. There was a significant negative
association between GSTT1 expression and patient
age (r = −0.570; P = 0.011). There were no significant
associations among patient age, Gleason score, total
serum PSA, and GSTs in tumor tissue.

From 19 patients, 20 samples of PCA, PIN, and
benign tissue from the peripheral prostate were
examined (Table). GSTA expressions were stronger in
benign epithelium than in prostate tumor epithelium
(Table). Of positive GSTA expression, 68% occurred
in benign epithelium; 37% of PIN and 11% of tumors
were considered to have GSTA expression (Table).
Figure 1 shows that strong nuclear and cytoplasmic
staining with GSTA was observed in the basal and
secretory cells of PIN cells (Figure 1).

Discussion
In this study, we investigated the association of
neoplastic transformation in prostate tissue and the
protein expression of GSTP, GSTM4, GSTA, and

Table. Expressions of GSTA, GSTP, GSTT1, and GSTM4 in benign epithelium (BE), PIN, and PCA.
GSTA

GSTT1

GSTM4

GSTP

13 (68)

SS, n
(%)
4 (21)

NS, n (%) WS, n (%) SS, n (%) NS, n (%) WS, n (%) SS, n (%) NS, n (%) WS, n (%) SS, n (%) NS, n (%) WS, n (%)
BE

6 (32)

11 (58)

2 (10)

4 (21)

14 (74)

1 (5)

9 (47)

7 (36)

3 (16)

2(11)

PIN

12 (63)

5 (26)

2 (11)

4 (21)

7 (37)

8 (42)

8 (42)

5 (26)

6 (32)

3(16)

7 (37)

9 (47)

PCA

15 (79)

4 (11)

-

5 (26)

11 (58)

3 (16)

12 (63)

6 (32)

1 (5)

13(68)

5 (26)

1 (6)

NS: negative staining (0), WS: weak staining (1), SS: strong staining (2).
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Figure 1. Nuclear and cytoplasmic positive staining with GSTA
was observed in secretory cells (GSTA, 400×).

GSTT1 isoenzymes. GSTs are a family of isoenzymes
that play an important role in protecting cells from
cytotoxic and carcinogenic agents. GSTs are divided
into 7 subclasses: GSTA, GSTM, GSTP, GSTT, GSTS,
GSTO, and GSTZ (8). The alpha, mu, pi, and theta
subclasses are mostly expressed in mammalian
tissues, with GSTP (the major class of the GSTs)
being the most abundant in the urinary, respiratory,
and gastrointestinal systems and thus in the prostate
(9,10). GSTP protein plays a role in toxin excretion
and metabolism. Loss of GSTP function may render
prostate cells vulnerable to genome damage mediated
by environmental carcinogens that may be GSTP
substrates, including oxidants, such as those arising
from prostate inflammation, and electrophiles,
which may be contributed via dietary exposure to
heterocyclic aromatic amine carcinogens (6). To the
best of our knowledge, this is the first study offering
a comprehensive description of the 4 classes of GST
isoenzymes in PCA tissues.
Our findings were consistent with those of
Bostwick et al. (11); most of the benign prostate
tissues expressed GSTP (P < 0.05). Contrary to these
findings, there was increased expression of GSTP in
other cancers such as breast, colon, stomach, pancreas,
bladder, lung, and larynx (12−15). Induction of
the enzymes in these cancers could be an adaptive
response to stress or to chemical agents, or they could
have an increased half-life of hypermethylated gene
products.
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Figure 2. Nuclear and cytoplasmic positive staining with
GSTM4 was observed in basal and secretory cells of
PIN cells (GSTM4, 200×).

In the current study, GSTP expression decreased
with the neoplastic transformation of the prostate, as
was also found by Moskaluk et al. (16), and 32% of
the tumors stained with GSTP in our study. GSTPpositive tumors were moderately differentiated
tumors in this study.
Our results for GSTA and GSTM4 are in agreement
with those of previous studies (10,11,17,18), whereas
Parsons et al. found that GSTA was nearly absent
in normal epithelium and was stained strongly
in prostatic inflammatory atrophy (3). GSTA
was identified in both normal prostate tissue and
prostate cancer by Murray et al. (17). In a study by
Bostwick et al. (11), GSTA displayed the lowest level
of expression, with diffuse weak staining in scattered
cells (<1%) in high-grade PIN and PCA. Only 11%
of carcinomas were positive for GSTA in this work.
It was reported that GSTP expression may also be
predictive of patient outcome. For example, in breast
cancer, GSTP expression was inversely related to
grade (19) and probably related to drug resistance;
other studies found that GSTP expression was a
prognostic indicator (20). We found no relationship
between GSTP expression and Gleason grade in
prostate cancer and no statistically significant
difference between other GSTs and Gleason grade,
age, and serum PSA. There are very few studies about
the correlation of GSTs with these clinical parameters
in the literature.
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Figure 3. Mild expression of GSTT1 in PIN and in carcinoma
(GSTT1, 400×).

Figure 4. Mild expression in PIN and loss of GSTP expression in
carcinoma (GSTP, 200×).

Through genetic research, the loss of expression
of GSTP was found to be the most common genetic
alteration in prostate cancer (21−24). In our work,
GSTP expression in PIN was higher than the
expression in carcinoma, and this was statistically
significant (P < 0.05). The results of Srivastava et
al. indicated that the null genotypes of GSTM1 and
GSTT1 and the G allele of GSTP1 are associated with
a higher risk of prostate cancer than controls (25).

associated with hypermethylation of deoxycytidine
residues (CG islands) in the 59-regulatory region of
the gene. Hypermethylation in the promoter region
of GSTP1 appears to be a frequent and early event in
prostate cancer development (6,39−44).

Some genetic analytical studies could not address
whether GST polymorphisms have an effect on
the clinical behavior of prostate cancer or other
clinicopathologic attributes. The metaanalysis cannot
exclude the possibility that other polymorphisms in
GST genes may still be useful to pursue. Moreover,
these studies could not address gene−gene or gene−
environmental interactions. Some other studies
showed a significant relation between prostate
carcinoma and genetic polymorphisms (7,26−37).
Interindividual differences in cancer susceptibility
may be mediated partially through polymorphic
variability in the bioactivation and detoxification of
carcinogens.
Rebbeck et al. reported that men who did not have
homozygous deletions at GSTT1 were at increased
risk of prostate carcinoma (1). Other studies suggest
that individuals homozygous for the polymorphic
GSTP1 genotype had a decreased risk of prostate
cancer (38). Loss of GSTP1 gene expression is

In our study, the GSTA class displayed the lowest
level of expression in PIN and PCA. GSTP expression
was lower in PCA tissue than in PIN (P < 0.05). There
was a significant negative association between GSTT1
expression and patient age; however, we did not find
a statistically significant association among patient
age, Gleason score, and total serum PSA and GSTs
in tumor tissue. These results suggest that the GST
population, owing to reduction or loss of expression
of multiple GSTs, especially GSTP and the alpha class,
plays a role in tumor growth and carcinogenesis of
the prostate.
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